Amanda Davis, APRN
Family · Fort Smith, ARNPI 1790220143
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 89.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $18,974 and has fallen 72.6% since, to $5,191 in 2025. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $231.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$42K
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$446
- Ipsen Biopharmaceuticals, Inc$245
- Regeneron Healthcare Solutions, Inc.$76
- Madrigal Pharmaceuticals$58
- plus $234 from 11 others
What the payments were for
- Consulting fees$7,76017%
- Speaking & faculty fees$22,16048%
- Travel & lodging$12,70627%
- Food & beverage$3,8598%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 126 | $41,612 |
| AbbVie | 27 | $3,812 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $446 |
| Ipsen Biopharmaceuticals, Inc | 14 | $245 |
| Regeneron Healthcare Solutions, Inc. | 2 | $76 |
| Madrigal Pharmaceuticals | 2 | $58 |
| Medtronic | 1 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Merck | 2 | $27 |
| Johnson & Johnson | 1 | $25 |
| Orphalan Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,485 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 38 | $936,351 |
| Humira(Cf) PenAdalimumab | 12 | $83,666 |
| XifaxanRifaximin | 23 | $75,288 |
| LinzessLinaclotide | 85 | $47,562 |
| Entecavir | 35 | $10,197 |
| Ursodiol | 32 | $3,906 |
| Tenofovir Disoproxil Fumarate | 46 | $3,535 |
| Sucralfate | 50 | $2,986 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,218 |
| DexilantDexlansoprazole | 12 | $1,945 |
| Omeprazole | 163 | $1,439 |
| Colestipol Hcl | 20 | $1,071 |
| Pantoprazole Sodium | 129 | $826 |
| Dicyclomine Hcl | 43 | $584 |
| Famotidine | 45 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $41,612 | $936,35138 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $446 | $75,28823 claims |
| AbbVieLinzess | $3,812 | $47,56285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Fort Smith
- Nina CopelandFort Smith$207K
- Scarlett BoneFort Smith$16K
- Nathan WilliamsonFort Smith$15K
- Yong OunpraseuthFort Smith$14K
- Karen WilliamsFort Smith$11K
- Nycole OliverFort Smith$10K
- Bentlee RundellFort Smith$10K
- Nata MatthewsFort Smith$10K
- Emily ChristensenFort Smith$9K
- Karen ThriftFort Smith$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.